The current study was carried out to evaluate the ameliorative effect of fucoidan against aflatoxicosis-induced hepatorenal toxicity in streptozotocin-induced diabetic rats. Sixty-four Wister albino male rats were randomly assigned into eight groups (8 rats each) that received normal saline, fucoidan (FUC) at 100 mg/kg/day orally for 4 weeks, streptozotocin (STZ) at 50 mg/kg/i.p. single dose, STZ plus FUC, aflatoxin B1 (AFB1) at 50 μg/kg/i.p. after one month of the beginning of the experiment for 2 weeks, AFB1 plus FUC, STZ plus AFB1, or STZ plus AFB1 and FUC. Injection of rats with STZ induced hyperglycemia. Rats with STZ-induced diabetes, with or without AFB1 intoxication, had significantly elevated activities of serum aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase, and levels of serum urea, creatinine, cholesterol, 8-oxo-2′-deoxyguanosine, interleukin-1β, interleukin-6, and tumor necrosis factor-α. In addition, these rats exhibited increased lipid peroxidation and reduced glutathione concentration and activities of superoxide dismutase, catalase, and glutathione peroxidase enzymes in the hepatic and renal tissues. In contrast, administration of FUC to diabetic rats, with or without AFB1 intoxication, ameliorated the altered serum parameters, reduced oxidative stress, DNA damage, and inflammatory biomarkers, and enhanced the antioxidant defense system in the hepatic and renal tissues. These results indicated that FUC ameliorated diabetes and AFB1-induced hepatorenal injuries through alleviating oxidative stress, DNA damage, and inflammation.

1. Introduction

Diabetes mellitus (DM) is a leading cause of morbidity and mortality worldwide. In developing countries, DM ranks as the 5th most common cause of death [1]. Diabetes mellitus is classified into two types: insulin-dependent (that results from destruction of pancreatic β cells of Langerhans) and noninsulin-dependent (that results from defects in insulin action and/or secretion) [2]. Extensive research has shown that inflammation and oxidative stress are implicated in the development and complications of DM [3]. Streptozotocin (STZ) is used experimentally to induce DM in animals.
because it targets the β cells of Langerhans and induces permanent hyperglycemia in experimental animals [4].

Aflatoxins are produced by Aspergillus flavus, Aspergillus parasiticus, and Aspergillus niger as secondary metabolites. Humans are exposed to aflatoxins through ingestion of contaminated food [5]. Storage of crops, such as corn and peanuts at excessive heat and humidity for long times, leads to proliferation of fungal spores and production of aflatoxins. The most prevalent and toxic aflatoxin is aflatoxin B1 (AFB1) [6]. Its toxic and carcinogenic activities are due to its bioactivation into AFB1-8,9-epoxide by microsomal cytochrome P450. The resulting metabolite binds to DNA, RNA, and proteins, resulting in hepatic and renal damage [7]. Exposure of rats and pigs to AFB1 stimulates mRNA expression of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and interleukin-6 (IL-6) [8]. The effects of AFB1 exposure depend on the dose and duration of treatment [6].

To the best of our knowledge, studies concerning the effect of mycotoxins on DM subjects are still rare. Although the liver plays vital roles in carbohydrate metabolism and regulation of blood glucose level, it is the target organ for AFB1 [9]. Intoxication of T1DM mice with AFB1-disordered T1DM elevated energy-producing mechanisms, gluconeogenesis, lipid, and oxidative phosphorylation, reduced major urinary protein 1, insulin sensitivity indicator, and subsequently elevated blood glucose level [10]. There is a positive interaction between AFB1 and diabetes in human subjects [11]. In addition, ochratoxin A induces toxic effects on the pancreatic tissue in a rat [12].

Fucoidans (FUCs) are highly sulfated polysaccharides, isolated from the cell walls of various species of brown seaweeds, such as Saccharina japonica, Undaria pinnatifida, and Sargassum hemiphyllum, and some animal species as sea cucumber [13]. In vitro and in vivo studies showed that FUCs have various biological activities such as hypoglycemic, nephroprotective, antioxidant, anti-inflammatory, anticoagulant, and antiviral effects [14, 15]. Many strategies are used to inhibit the development and progression of DM which rely on alleviating oxidative stress and inflammation [16]. The current study was aimed to evaluate the ameliorative potential of FUC against aflatoxicosis-induced hepatorenal toxicity in streptozotocin-induced DM in rats.

2. Materials and Methods

2.1. Chemicals. Streptozotocin and aflatoxin B1 were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Fucoidan (Laminaria japonica, 500 mg/capsule) was obtained from Absunutrix Lyfetrition (USA). The kits, used for determination of blood glucose and serum metabolites levels, were obtained from BioDiagnostics Co. (Cairo, Egypt). ELISA kits, used to measure the serum levels of inflammatory cytokines, were obtained from R&D (Mannheim, Germany), while the kits for 8-OhD measurement were purchased from Cayman Chemical (Co., MI, USA).

2.2. Animals. Sixty-four Wister albino male rats of 180 to 200 g weights were bought from the Egyptian Organization for Biological Products and Vaccines. Rats were kept at 25 ± 2°C and 12 h light/dark cycle in a well-ventilated room. Rats were given access to food and water ad libitum. Rats were maintained under these environmental conditions for one week for adaption before the beginning of the experiment. The experimental design was approved by the Research Ethical Committee of the Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt (Approval No. 201616).

2.3. Experimental Design. Rats were randomly assigned into eight different experimental groups (8 rats each).

**The control rats** were given normal physiological saline.

**The second group** rats were given FUC at 100 mg/kg/day orally [17] between weeks 5 and 8 of the experiment.

**The third group** rats were administered STZ at 50 mg/kg/i.p. (dissolved in 0.1 mmol/l citrate buffer, pH 4.5) after 12 h fasting at the beginning of the experiment [18].

**The fourth group** rats were administered STZ as the third group and FUC as the second group.

**The fifth group** rats were given AFB1 at 50 µg/kg/i.p. during the fifth and sixth weeks [19].

**The sixth group** rats were administered AFB1 as the fifth group and FUC as the second group.

**The seventh group** rats were administered STZ as the third group and AFB1 as the fifth group.

**The eighth group** rats were administered STZ as the third group, AFB1, as the fifth group, and FUC as the second group.

The experiment design is illustrated in Figure 1.

2.4. Blood and Tissue Sampling. Blood samples were collected at the end of the experiment. Blood samples were left to clot at room temperature for 30 min and then centrifuged at 2500 rpm for 15 min, and sera samples were separated and stored at -20°C till biochemical assessment. The rats were later sacrificed by decapitation and the liver and kidney tissues were collected and washed with normal physiological saline solution. Then, tissue samples were homogenized in ice-cold buffer containing 50 mM sodium phosphate-buffered saline (100 mM Na2HPO4/NaH2PO4) (pH 7.4),
 containing 0.1 mM EDTA then centrifuged for 30 minutes at 5000 rpm. The supernatant was collected and maintained at -80°C for subsequent analysis.

2.5. Biochemical Assays. The initial and fasting blood glucose levels were colorimetrically assayed according to Trinder [20]. The activities of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were analyzed according to Reitman and Frankel [21]. The activity of serum alkaline phosphatase (ALP) was evaluated according to Tietz et al. [22].

The levels of serum total cholesterol according to (Richmond, 1973; Allain et al. 1974), urea, and creatinine were evaluated spectrophotometrically (Coulombe and Favreau [23] and Larsen [24]), respectively.

The tissue homogenates were used to determine the concentrations of malondialdehyde (MDA) [25], nitric oxide (NO) [26], reduced glutathione (GSH) [27], superoxide dismutase (SOD) [28], glutathione peroxidase (GSH-Px) [29], and catalase (CAT) [30] activities in both hepatic and renal tissues according to the referenced methods.

2.6. Evaluation of DNA Oxidation Biomarker. The concentration of serum 8-oxo-2′-deoxyguanosine (8-OHdG) was determined by using 8-OHdG competitive assay kit (Cayman Chemical Co., MI, USA) that detects free 8-OHdG and DNA-pound 8-OHdG.

2.7. Determination of Inflammatory Biomarkers. The serum levels of IL-1β, IL-6, and TNF-α were determined, by here using commercially available ELISA kits obtained from R&D (Mannheim, Germany) according to the manufacturers’ instructions.

2.8. Statistical Analysis. All data were expressed as the means ± SEM, using SPSS software (version 20 for Windows, Armonk, NY). Data were analyzed by here using one-way ANOVA followed by Duncan’s post hoc test to test the significant differences between experimental groups. The differences among groups were considered statistically significant at $P \leq 0.05$.

3. Results

3.1. Fucoidan Reduced STZ-Induced Hyperglycemia in Rats. Intraperitoneal STZ administration was associated with significant increases in initial and fasting blood glucose levels compared with control rats. However, treatments of diabetic rats (with or without AFB1 intoxication) with FUC (4th and 8th groups) significantly decreased blood glucose levels compared to diabetic, nontreated rats (3rd and 7th groups). On the other hand, both AFB1 and FUC (2nd, 5th, and 6th groups) had no significant effects on fasting blood glucose levels (Table 1).

3.2. Fucoidan Normalized AFB1-Induced Alterations in Serum Liver Function Biomarkers in Diabetic Rats. Treatment of rats with STZ and/or AFB1 (3rd, 5th, and 7th groups) was associated with significant increases in serum activities of ALT, AST, and ALP (that was most prominent in the combination group). In contrast, treatment of diabetic rats with or without AFB1 intoxication with FUC (4th, 6th, and 8th groups) normalized the activities of serum AST, ALT, and ALP. FUC alone had no significant effect on the activities of serum AST, ALT, and ALP compared to control rats (Table 1).

3.3. Fucoidan Ameliorated AFB1-Induced Alteration in Serum Kidney Function Biomarkers in Diabetic Rats. Treatment of rats with STZ and/or AFB1 (3rd, 5th, and 7th groups) was associated with significant increases in serum urea and creatinine levels (that was most prominent in the combination group). However, treatment of diabetic rats with or without AFB1 intoxication with FUC (4th, 6th, and 8th groups) significantly reduced serum urea and creatinine levels, compared with the 5th and 7th groups. Treatment with FUC alone was not associated with significant changes in serum urea and creatinine levels compared with the control rats (Table 1).

3.4. Fucoidan Normalized AFB1-Induced Oxidative Stress in Rat Hepatic and Renal Tissues. Administration of STZ and/or AFB1 (3rd, 5th, and 7th groups) was associated with significantly increased serum cholesterol levels in comparison to control rats. However, treatment of diabetic or nondiabetic rats intoxicated with AFB1, with FUC (4th, 6th, and 8th groups), normalized serum cholesterol levels, compared with the 3rd, 5th, and 7th groups. Treatment with FUC alone did not cause significant changes in serum cholesterol levels compared with the control rats (Table 1).

3.5. Fucoidan Normalized AFB1-Induced Oxidative Stress in Rat Hepatic and Renal Tissues. Administration of rats with streptozotocin and/or AFB1 (3rd, 5th, and 7th groups) was associated with significant increases in hepatic and renal tissue concentrations of MDA and NO in comparison to control rats. However, treatment of diabetic and nondiabetic rats intoxicated with AFB1, with FUC (4th, 6th, and 8th groups) normalized MDA and NO concentrations in both hepatic and renal tissues (Tables 2 and 3).

In contrast, induction of diabetes and/or aflatoxin intoxication significantly reduced GSH concentrations and GSH-Px, SOD, and CAT activities in both hepatic and renal tissues in the 3rd, 5th, and 7th groups in comparison to the control rats. Treatment of diabetic and nondiabetic rats intoxicated with AFB1, with FUC (4th, 6th, and 8th groups) reversed the effects of both diabetes and AFB1 intoxication on the aforementioned parameters. Treatment with FUC alone significantly elevated GSH concentration and GSH-Px, SOD, and CAT activities in the hepatic and renal tissues compared with the control group (Tables 2 and 3).

3.6. Fucoidan Normalized AFB1-Induced Elevation of Serum Levels of DNA Oxidation Biomarker and Inflammatory Cytokines. Induction of diabetes and/or AFB1 intoxication in the 3rd, 5th, and 7th groups was associated with significantly elevated serum 8-OHdG, IL-1β, IL-6, and TNF-α levels, compared to the control group. However, treatment of diabetic and nondiabetic rats intoxicated with AFB1, with FUC (4th, 6th, and 8th group) reduced serum 8-OHdG, IL-1β, IL-6, and TNF-α levels compared to nontreated rats (3rd, 5th, 6th, and 8th groups) normalized serum cholesterol levels, compared with diabetic and nondiabetic rats intoxicated with AFB1, with FUC (4th, 6th, and 8th groups) significantly reduced serum urea and creatinine levels, compared with the 5th and 7th groups. Treatment with FUC alone, however, did not cause significant changes in serum cholesterol levels compared with the control rats (Table 1).
Table 1: Effects of fucoidan on serum biochemical parameters of diabetic rats intoxicated with aflatoxin B₁.

| Parameters          | Control | FUC       | STZ      | STZ+FUC | AFB₁   | AFB₁+FUC | STZ+AFB₁ | STZ+AFB₁+FUC |
|---------------------|---------|-----------|----------|---------|--------|----------|----------|--------------|
| i blood glucose (mg/dl) | 83.37ᵇ ± 3.50 | 84.21ᵇ ± 3.75 | 281.29ᵇ ± 5.80 | 274.42ᵃ ± 5.82 | 91.19ᵇ ± 4.12 | 82.36ᵇ ± 2.59 | 285.54ᵃ ± 6.42 | 276.22ᵃ ± 6.39 |
| f blood glucose (mg/dl) | 89.53ᶜ ± 2.1  | 81.24ᶜ ± 3.68 | 305.12ᶜ ± 8.14 | 140.91ᵇ ± 5.82 | 87.88ᶜ ± 3.62 | 90.68ᶜ ± 5.00 | 322.45ᵃ ± 7.95 | 128.88ᵇ ± 5.40 |
| AST (U/l)           | 26.56ᵈ ± 0.32 | 24.49ᵈ ± 1.19 | 70.28ᶜ ± 4.13 | 31.7ᵈ ± 1.36 | 84.67ᵇ ± 4.42 | 34.33ᵈ ± 2.41 | 149.73ᵇ ± 5.82 | 33.08ᵈ ± 2.08   |
| ALT (U/l)           | 15.23ᵈ ± 0.63 | 15.19ᵈ ± 0.24 | 43.64ᶜ ± 3.25 | 20.17ᵈ ± 0.95 | 53.67ᵇ ± 3.19 | 18.58ᵈ ± 1.12 | 67.49ᵃ ± 3.54 | 18.53ᵈ ± 1.05   |
| ALP (U/l)           | 28.90ᵈ ± 1.40 | 26.13ᵈ ± 0.84 | 77.56ᶜ ± 2.50 | 34.05ᵈ ± 1.47 | 87.33ᵇ ± 3.63 | 32.09ᵈ ± 2.23 | 105.97ᵇ ± 4.41 | 32.43ᵈ ± 2.34   |
| Cholesterol (mg/dl) | 91.76ᵈ ± 4.51 | 88.07ᵈ ± 3.91 | 189.16ᵇ ± 5.08 | 111.64ᵈ ± 481 | 158.62ᶜ ± 4.45 | 91.86ᵈ ± 4.43 | 215.87ᵃ ± 6.57 | 101.45ᵈ ± 4.79  |
| Urea (mg/dl)        | 27.7ᵃ ± 1.18  | 26.51ᶜ ± 1.22 | 52.36ᶜ ± 1.18 | 35.72ᶜ ± 1.78 | 61.77ᵇ ± 4.41 | 38.32ᵈ ± 2.34 | 75.82ᵈ ± 3.30 | 43.11ᵈ ± 2.52   |
| Creatinine (mg%)    | 0.33ᵈ ± 0.05  | 0.30ᵈ ± 0.07  | 1.21ᶜ ± 0.05  | 0.54ᵈ ± 0.04  | 3.16ᵇ ± 0.28  | 0.77ᵈ ± 0.04  | 4.72ᵃ ± 0.36  | 0.92ᵈ ± 0.05    |

Data are expressed as the means ± SEM (n = 8). i blood glucose: initial blood glucose; f blood glucose: fasting blood glucose; FUC: fucoidan; STZ: streptozotocin; AFB₁: aflatoxin B₁; ALT: alanine transferase; AST: aspartate transferase; ALP: alkaline phosphatase. Values having different superscripts within the same row are significantly different (P ≤ 0.05).
Table 2: Effects of fucoidan against aflatoxin-induced changes in diabetic rats' liver tissue oxidative stress and antioxidant biomarkers.

| Parameters   | Control          | FUC              | STZ              | STZ+FUC         | AFB₁             | AFB₁+FUC         | STZ+AFB₁         | STZ+AFB₁+FUC     |
|-------------|------------------|------------------|------------------|-----------------|------------------|-----------------|-----------------|-----------------|
| MDA (nmol/g)| 189.96 ± 12.42   | 182.14 ± 10.18   | 318.25 ± 14.17   | 225.00 ± 9.77   | 242.06 ± 20.19   | 204.29 ± 6.11   | 595.82 ± 20.86   | 211.84 ± 8.52    |
| NO (µmol/g) | 106.51 ± 5.54    | 87.54 ± 3.27     | 161.89 ± 6.38    | 110.95 ± 2.80   | 200.48 ± 6.69    | 117.93 ± 6.12   | 275.73 ± 11.13   | 125.12 ± 2.93    |
| GSH (mg/g)  | 189.63 ± 8.35    | 225.83 ± 7.08    | 118.98 ± 6.62    | 181.58 ± 6.32   | 108.79 ± 5.13    | 176.84 ± 11.07  | 95.17 ± 4.51     | 159.16 ± 6.32    |
| GSH-Px (mol/g) | 186.26 ± 14.42  | 225.11 ± 11.72   | 95.43 ± 4.16     | 183.66 ± 6.32   | 76.71 ± 5.43     | 174.44 ± 6.33   | 62.42 ± 5.46     | 162.48 ± 4.94    |
| SOD (U/g)   | 30.63 ± 1.17     | 36.90 ± 1.56     | 13.28 ± 1.32     | 30.43 ± 2.62    | 9.59 ± 0.48      | 28.94 ± 1.43    | 5.78 ± 0.87      | 27.69 ± 1.93     |
| CAT (U/g)   | 3.42 ± 0.20      | 3.97 ± 0.18      | 1.79 ± 0.14      | 3.18 ± 0.16     | 1.13 ± 0.09      | 2.99 ± 0.14     | 1.01 ± 0.08      | 3.18 ± 0.16      |

Data are expressed as the means ± SEM (n = 8). FUC: fucoidan; STZ: streptozotocin; AFB₁: aflatoxin B₁; MDA: malondialdehyde; NO: nitric oxide; GSH: reduced glutathione; GSH-Px: glutathione peroxidase; SOD: superoxide dismutase; CAT: catalase. Values having different superscripts within the same row are significantly different (P ≤ 0.05).
Table 3: Effects of fucoidan against aflatoxin-induced changes in diabetic rats' renal tissue oxidative stress and antioxidant biomarkers.

| Parameters       | Control | FUC     | STZ     | STZ+FUC | AFB₁ | AFB₁+FUC | STZ+AFB₁ | STZ+AFB₁+FUC |
|------------------|---------|---------|---------|---------|------|----------|----------|--------------|
| MDA (nmol/g)     | 68.72⁺  | 62.30⁺  | 149.21⁺ | 76.72⁺  | 197.69⁺ | 87.93⁺   | 287.65⁺  | 108.39⁺      |
| NO (µmol/g)      | 92.88⁺  | 78.82⁺  | 194.32⁺ | 98.70⁺  | 243.29⁺ | 111.46⁺  | 315.74⁺  | 138.41⁺      |
| GSH (mg/g)       | 83.67ᵇ  | 99.70ᵇ  | 46.55ᵈ  | 77.55ᵇ  | 39.05ᵈ  | 68.67ᶜ   | 16.55ᶜ   | 57.42ᶜ       |
| GSH-Px (mol/g)   | 50.22ᵇ  | 61.43ᵃ  | 21.43ᵉ  | 46.91ᵇ  | 18.93ᵉ  | 43.00ᵇ   | 14.84ᶜ   | 40.34ᵇ       |
| SOD (U/g)        | 18.18ᵇ  | 22.13ᵃ  | 9.14ᵉ   | 15.55⁺  | 6.83⁺   | 14.98ᶜ   | 4.40ᵈ    | 13.00ᵈ       |
| CAT (U/g)        | 2.05ᵇ   | 2.69⁺   | 0.71⁺   | 1.79ᵇ   | 0.65⁺   | 1.43⁺    | 0.49⁺    | 1.03ᵈ        |

Data are expressed as the means ± SEM (n = 8). FUC: fucoidan; STZ: streptozotocin; AFB₁: aflatoxin B₁; MDA: malondialdehyde; NO: nitric oxide; GSH: reduced glutathione; GSH-Px: glutathione peroxidase; SOD: superoxide dismutase; CAT: catalase. Values having different superscripts within the same row are significantly different (P ≤ 0.05).
and 7th groups). FUC itself had no significant effects on the serum 8-OHdG, IL-1β, IL-6, and TNF-α levels in comparison to control rats (Figure 2).

4. Discussion

Great numbers of animals and people suffering from diabetes mellitus worldwide and its incidence increase in steady state and the number of diabetic patients has been expected to reach about 300 million in 2025 [31–33]. Numerous human and animals all over the world are subjected to mycotoxins because they frequently occur in food and feed stuffs [34]. The most prevalent and toxic aflatoxin worldwide is AFB1 [35–37]. Aflatoxin B₁ induces several cellular damages through generation of free radicals and induction of lipid peroxidation resulting in oxidative stress in animals or humans. Oxidative stress plays indispensable role in AFB₁-induced toxicity [38, 39] through activation of inflammatory cytokines such as TNF-α, IL-1β, and IL-6 [40]. Thus, exposure of diabetic patients to mycotoxosis is unavoidable that is adversely affecting their health through induction of oxidative stress and subsequent inflammation.

The current study showed that injection of rats with STZ induced hyperglycemia, probably due to the irreversible cytotoxic effects of STZ on the β cells of the pancreas resulting in insulin deficiency [41]. Oxidative stress is implicated in this cytotoxic effect. In addition, induction of both diabetes and/or aflatoxicosis in rats resulted in elevated activities of liver function biomarkers, which can be explained by ROS generation, lipid peroxidation, and depleted antioxidant defense system in the hepatic tissue. These effects result in hepatocyte necrosis and release of hepatic enzymes into the circulation [42, 43]. Similarly, injection of rats with STZ and/or AFB₁ significantly increased serum levels of urea and creatinine. These findings were in line with those of Era-slan et al. [44] and Zabad et al. [45]. This may be attributed to hyperglycemia and/or AFB₁-induced ROS leading to necrosis of proximal tubular epithelial cells [44, 45]. To confirm the role of MD and AFB₁-induced oxidative stress in disturbance of hepatorenal function, our study revealed that DM and/or

![Figure 2: The ameliorative effect of FUC against AFB₁-induced alteration in serum levels of 8-OHdG (a), IL-1β (b), IL-6 (c), and TNF-α (d) in streptozotocin-induced diabetic rats. Data are presented as the mean ± SEM. Columns having different letters are significantly different (P ≤ 0.05).](image-url)
AFB₁ intoxication in rats induced oxidative stress in both hepatic and renal tissues as evidenced by the increased levels of MDA and NO and reduced concentration of GSH and activities of GSH-Px, SOD, and CAT (Tables 2 and 3). These results are in accordance with prior studies [46, 47]. In the presence of nitric oxide synthase, superoxide and NO react to generate peroxynitrite that injures the cell membrane and cellular biomolecules [48]. Further, these radicals attack the cellular DNA, as evidenced by the increased levels of serum 8-OHdG (Figure 1). In addition, AFB₁ metabolites form AFB₁-DNA adducts that induce DNA and cell damages and inhibit enzyme and protein synthesis through binding to nucleoproteins and nucleic acids [49]. Diabetes mellitus and AFB₁ intoxication-induced oxidative stress in this study were associated with increased production of proinflammatory cytokines, IL-1β, IL-6, and TNF-α (Figure 1) leading to hepatorenal injuries and the elevation of activities and levels of their function biomarkers. There is extensive documentation of renal injuries and the elevation of activities and levels of cytokines, IL-1β, IL-6, and TNF-α. These results are in accordance with prior studies [46, 47]. In the activities of GSH-Px, SOD, and CAT (Tables 2 and 3). These results are in accordance with prior studies [46, 47]. In conclusion, DM and AFB₁-induced hepatorenal injuries are probably mediated by oxidative stress, DNA damage, and inflammation. However, treatment with FUC ameliorated DM and AFB₁-induced hepatorenal injuries, mostly due to its antioxidant and anti-inflammatory effects.

**Abbreviations**

- MDA: Malondialdehyde
- NO: Nitric oxide
- CAT: Catalase
- SOD: Superoxide dismutase
- GSH-Px: Glutathione peroxidase
- GSH: Reduced glutathione
- CAT: Catalase
- NO: Nitric oxide
- GSH-Px: Glutathione peroxidase
- SOD: Superoxide dismutase
- GSH: Reduced glutathione
- CAT: Catalase
- NO: Nitric oxide
- GSH-Px: Glutathione peroxidase
- SOD: Superoxide dismutase
- GSH: Reduced glutathione
- CAT: Catalase
- NO: Nitric oxide

**Data Availability**

All data will be available when required.

**Conflicts of Interest**

All authors declare that there is no conflict of interests.

**Acknowledgments**

This research was funded by the Deanship of Scientific Research at Princess Nourah Bint Abdulrahman University through the Fast-track Research Funding Program. In addition, this project was supported by the King Saud University, Deanship of Scientific Research, College of Science Research Center.

**References**

[1] G. A. Roth, D. Abate, K. H. Abate et al., “Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017,” *The Lancet*, vol. 392, no. 10159, pp. 1736–1788, 2018.

[2] American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” *Diabetes Care*, vol. 36, Supplement 1, pp. S67–S74, 2013.

[3] U. Asmat, K. Abad, and K. Ismail, “Diabetes mellitus and oxidative stress—A concise review,” *Saudi Pharmaceutical Journal*, vol. 24, no. 5, pp. 547–553, 2016.
Oxidative Medicine and Cellular Longevity

[4] M. Radenković, M. Stojanović, and M. Prostran, “Experimental diabetes induced by alloxan and streptozotocin: the current state of the art,” Journal of Pharmacological and Toxicological Methods, vol. 78, pp. 13–31, 2016.

[5] D. K. Mahato, K. E. Lee, M. Kamle et al., “Aflatoxins in food and feed: an overview on prevalence, detection and control strategies,” Frontiers in Microbiology, vol. 10, pp. 2266–2266, 2019.

[6] B. R.ushing and M. I. Selim, “Aflatoxin B1: a review on metabolism, toxicity, occurrence in food, occupational exposure, and detoxification methods,” Food and Chemical Toxicology, vol. 124, pp. 81–100, 2019.

[7] P. Kumar, D. K. Mahato, M. Kamle, T. K. Mohanta, and S. G. Kang, “Aflatoxins: a global concern for food safety, human health and their management,” Frontiers in Microbiology, vol. 7, article 2170, 2017.

[8] G. Qian, L. Tang, X. Guo et al., “Aflatoxin B1 modulates the expression of phenotypic markers and cytokines by splenic lymphocytes of male F344 rats,” Journal of Applied Toxicology, vol. 34, no. 3, pp. 241–249, 2014.

[9] C. Ledda, C. Loreto, C. Zammit et al., “Non-infective occupational risk factors for hepatocellular carcinoma: a review,” Molecular Medicine Reports, vol. 15, no. 2, pp. 511–533, 2017.

[10] F.-J. Tsai, S.-Y. Chen, Y.-C. Liu, H.-Y. Liao, and C.-J. Chen, “The comparison of CHCA solvent compositions for improving LC-MALDI performance and its application to study the impact of aflatoxin B1 on the liver proteome of diabetes mellitus type 1 mice,” PLoS One, vol. 12, no. 7, article e0181423, 2017.

[11] C. Zheng, H. Zeng, J. Wang et al., “The association between aflatoxin exposure and primary hepatocellular carcinoma risks: a case-control study in Chongqing,” Zhonghua yu fang bo yue hao, vol. 51, no. 6, pp. 539–545, 2017.

[12] F. S. Alpsoy, S. Topsakal, M. Kilic, and O. Ozmen, “Dietary effects of ochratoxin A in female rats,” Toxins, vol. 9, no. 4, p. 144, 2017.

[13] M. Ale and A. Meyer, “Fucoidans from brown seaweeds: an update on structures, extraction techniques and use of enzymes as tools for structural elucidation,” RSC Advances, vol. 3, no. 22, pp. 8131–8141, 2013.

[14] Y. Wang, M. Xing, Q. Cao, A. Ji, H. Liang, and S. Song, “Biological activities of fucoidan and the factors mediating its therapeutic effects: a review of recent studies,” Marine Drugs, vol. 17, no. 3, p. 183, 2019.

[15] S. Luthuli, S. Wu, Y. Cheng, X. Zheng, M. Wu, and H. Tong, “Therapeutic effects of fucoidan: a review on recent studies,” Marine Drugs, vol. 17, no. 9, p. 487, 2019.

[16] S. Bajaj and A. Khan, “Antioxidants and diabetes,” Indian Journal of Endocrinology and Metabolism, vol. 16, Supplement 2, pp. S267–S271, 2012.

[17] G. H. Heeba and M. A. Morsy, “Fucoidan ameliorates steatohepatitis and insulin resistance by suppressing oxidative stress and inflammatory cytokines in experimental non-alcoholic fatty liver disease,” Environmental Toxicology and Pharmacology, vol. 40, no. 3, pp. 907–914, 2015.

[18] D. Onk, O. A. Onk, H. S. Erol et al., “Effect of melatonin on antioxidant capacity, inflammation and apoptotic cell death in lung tissue of diabetic rats,” Acta Cirurgica Brasileira, vol. 33, no. 4, pp. 375–385, 2018.

[19] A. Al-Ghasham, H. S. Ata, S. El-Deep, A.-R. Meki, and S. Shehada, “Study of protective effect of date and Nigella sativa on aflatoxin B1 toxicity,” International Journal of Health Sciences, vol. 2, no. 2, pp. 26–44, 2008.

[20] P. Trinder, “Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor,” Annals of Clinical Biochemistry: An International Journal of Biochemistry and Laboratory Medicine, vol. 6, no. 1, pp. 24–27, 1969.

[21] S. Reitman and S. Frankel, “A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases,” American Journal of Clinical Pathology, vol. 28, no. 1, pp. 56–63, 1957.

[22] N. W. Tietz, C. A. Burtis, P. Duncan et al., “A reference method for measurement of alkaline phosphatase activity in human serum,” Clinical Chemistry, vol. 29, no. 5, pp. 751–761, 1983.

[23] J. J. Couble and L. Favreau, “A new simple semimicro method for colorimetric determination of urea,” Clinical Chemistry, vol. 9, no. 1, pp. 102–108, 1963.

[24] K. Larsen, “Creatinine assay by a reaction-kinetic principle,” Clinica Chimica Acta, vol. 41, pp. 209–217, 1972.

[25] M. Mihara and M. Uchiyama, “Determination of malonaldehyde precursor in tissues by thiobarbituric acid test,” Analytical Biochemistry, vol. 86, no. 1, pp. 271–278, 1978.

[26] L. C. Green, D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum, “Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids,” Analytical Biochemistry, vol. 126, no. 1, pp. 131–138, 1982.

[27] E. Beutler, O. Duron, and B. M. Kelly, “Improved method for the determination of blood glutathione,” The Journal of Laboratory and Clinical Medicine, vol. 61, pp. 882–888, 1963.

[28] M. Nishikimi, N. Appaji, and K. Yagi, “The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen,” Biochemical and Biophysical Research Communications, vol. 46, no. 2, pp. 849–854, 1972.

[29] D. E. Paglia and W. N. Valentine, “Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase,” The Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158–169, 1967.

[30] H. Aebi, “[13] Catalase in vitro,” Methods in Enzymology, vol. 105, pp. 121–126, 1984.

[31] J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010.

[32] Ş. Topsakal and O. Ozmen, “Diabetes mellitus in humans and animals,” Veterinary Journal of Mehmet Akif Ersoy University, vol. 1, no. 1, pp. 47–57, 2016.

[33] J. C. Seidell, “Obesity, insulin resistance and diabetes—a worldwide epidemic,” British Journal of Nutrition, vol. 83, no. 51, pp. 55–58, 2000.

[34] J. Bünning, G. Westphal, A. Mönich, B. Hinnendahl, E. Hallier, and M. Müller, “Cytotoxicity of occupationally and environmentally relevant mycotoxins,” Toxicology, vol. 202, no. 3, pp. 199–211, 2004.

[35] “Modulatory effects of selenium and zinc on the immune system,” Folia Microbiologica, vol. 48, no. 3, pp. 417–426, 2003.

[36] L. Alpsoy, M. I. Selim, “Chapter twelve - Key roles of vitamins A, C, and E in aflatoxin B 1-induced oxidative stress,” in Vitamins & Hormones, vol. 86, pp. 287–305, 2011.

[37] S. M. Herzallah, “Aflatoxin B1 residues in eggs and flesh of laying hens fed aflatoxin B1 contaminated diet,” American Journal of Pathology, vol. 105, no. 5, pp. 1133–1139, 1979.
A. Vipin, R. Rao, N. K. Kurrey, K. A. Anu Appaiah, and N. Shanmugam, M. A. Reddy, M. Guha, and R. Natarajan, I. E. M. Zabad, M. N. Amin, and M. M. El-Shishtawy, J. S. Beckman and W. H. Koppenol, "Protective effect of vanillin on diabetic nephropathy by decreasing inflammation to enhance DNA damage in alveolar epithelial cells," Journal of Agricultural and Food Chemistry, vol. 51, no. 8, pp. 2409–2414, 2003.

J. Mehrzad, A. M. Malvandi, M. Alipour, and S. Hosseinkhani, "Environmentally relevant level of aflatoxin B1 elicits toxic pro-inflammatory response in murine CNS-derived cells," Toxicology Letters, vol. 279, pp. 96–106, 2017.

S. Arora, S. K. Ojha, and D. Vohora, "Characterisation of streptozotocin induced diabetes mellitus in Swiss albino mice," Global Journal of Agricultural Research, vol. 3, no. 2, pp. 81–84, 2009.

J.-J. Kim, J. Choi, M.-K. Lee et al., "Immunomodulatory and antidiabetic effects of a new herbal preparation (HemoHIM) on streptozotocin-induced diabetic mice," Evidence-based complementary and alternative medicine, vol. 2014, Article ID 461685, 8 pages, 2014.

G. Venkateswaran, J. Teixeira, L. Ç. Bayram, M. Y. Tekeli, M. Kanbur, and M. Karabacak, "Lupeol ameliorates aflatoxin B1-induced peroxidative hepatic damage in rats," Comparative biochemistry and physiology. Toxicology & Pharmacology: CBP, vol. 143, no. 3, pp. 333–339, 2006.

G. Eraslan, Z. S. Sarca, L. Ç. Bayram, M. Y. Tekeli, M. Kanbur, and M. Karabacak, "The effects of diosmin on aflatoxin-induced liver and kidney damage," Environmental Science and Pollution Research International, vol. 24, no. 36, pp. 27931–27941, 2017.

I. E. M. Zahad, M. N. Amin, and M. M. El-Shishtawy, "Protective effect of vanillin on diabetic nephropathy by decreasing advanced glycation end products in rats," Life Sciences, vol. 239, article 117088, 2019.

A. Vipin, R. Rao, N. K. Kurrey, K. A. Anu Appaiah, and G. Venkateswaran, "Protective effects of phenolics rich extract of ginger against aflatoxin B1-induced oxidative stress and hepatotoxicity," Biomedicine & Pharmacotherapy, vol. 91, pp. 415–424, 2017.

B. Al-Trad, H. Alkhateeb, W. Alsmadi, and M. Al-Zoubi, "Eugenol ameliorates insulin resistance, oxidative stress and inflammation in high fat-diet/streptozotocin-induced diabetic rat," Life Sciences, vol. 216, pp. 183–188, 2019.

J. S. Buckman and W. H. Koppenol, "Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly," American Journal of Physiology-Cell Physiology, vol. 271, no. 5, pp. C1424–C1437, 1996.

P. Shao, N. Guo, C. Wang et al., "Aflatoxin G1 induced TNF-α-dependent lung inflammation to enhance DNA damage in alveolar epithelial cells," Journal of Cellular Physiology, vol. 234, no. 6, pp. 9194–9206, 2019.

N. Shanmugam, M. A. Reddy, M. Guha, and R. Natarajan, "High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocyte cells," Diabetes, vol. 52, no. 5, pp. 1256–1264, 2003.

G. M. Meissonnier, P. Pinton, J. Laffitte et al., "Immunotoxicity of aflatoxin B1: impairment of the cell-mediated response to vaccine antigen and modulation of cytokine expression," Toxicology and Applied Pharmacology, vol. 231, no. 2, pp. 142–149, 2008.

L. Hou, F. Gan, X. Zhou et al., "Immunotoxicity of ochratoxin A and aflatoxin B1 in combination is associated with the nuclear factor kappa B signaling pathway in 3D4/21 cells," Chemosphere, vol. 199, pp. 718–727, 2018.

J. Wang, H. Liu, N. Li, Q. Zhang, and H. Zhang, "The protective effect of fucoidan in rats with streptozotocin-induced diabetic nephropathy," Marine Drugs, vol. 12, no. 6, pp. 3292–3306, 2014.

S.-Y. Sim, Y.-E. Shin, and H.-K. Kim, "Fucoidan from Undaria pinnatifida has anti-diabetic effects by stimulation of glucose uptake and reduction of basal lipolysis in 3T3-L1 adipocytes," Nutrition Research, vol. 65, pp. 54–62, 2019.

M. Boshy, F. Abdelhamidb, E. Richab, A. Ashshia, M. Gaitha, and N. Qustya, "Attenuation of CCH4 induced oxidative stress, immunosuppressive, hepatorenal damage by fucoidan in rats," Journal of Clinical Toxicology, vol. 7, p. 348, 2017.

M. M. Abdel-Daim, A. I. Abushouk, E. I. Bahbah et al., "Fucoidan protects against subacute diazinon-induced oxidative damage in cardiac, hepatic, and renal tissues," Environmental Science and Pollution Research, pp. 1–11, 2020.

A. A. AlKahtane, A. I. Abushouk, E. T. Mohammed et al., "Fucoidan alleviates microcytosis-LR-induced hepatic, renal, and cardiac oxidative stress and inflammatory injuries in mice," Environmental Science and Pollution Research, vol. 27, no. 3, pp. 2935–2944, 2020.

N. Mori, K. Nakasone, K. Tomimori, and C. Ishikawa, "Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection," World Journal of Gastroenterology, vol. 18, no. 18, pp. 2225–2230, 2012.

T. I. Imbs, A. V. Skriptsova, and T. N. Zryagintseva, "Antioxidant activity of fucose-containing sulfated polysaccharides obtained from Fucus evanescens by different extraction methods," Journal of Applied Phycology, vol. 27, no. 1, pp. 545–553, 2015.

R. Rodriguez-Jasso, S. Mussatto, L. Pastrana, C. Aguilar, and J. Teixeira, "Chemical composition and antioxidant activity of sulphated polysaccharides extracted from Fucus vesiculosus using different hydrothermal processes," Chemical Papers, vol. 68, no. 2, pp. 203–209, 2014.

X. Yu, Q. Zhang, W. Cui et al., "Low Molecular Weight Fucoidan Alleviates Cardiac Dysfunction in Diabetic Goto- Kakizaki Rats by Reducing Oxidative Stress and Cardiomycyte Apoptosis," Journal of Diabetes Research, vol. 2014, Article ID 420929, 13 pages, 2014.

H. Y. Park, M. H. Han, C. Park et al., "Anti-inflammatory effects of fucoidan through inhibition of NF-xB, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells," Food and Chemical Toxicology, vol. 49, no. 8, pp. 1745–1752, 2011.

T. Kuznetsova, "Fucoidan extracted from Fucus evanescens brown algae corrects immunity and hemostasis disorders in experimental endotoxemia," Bulletin of Experimental Biology and Medicine, vol. 147, no. 1, pp. 66–69, 2009.

J.-i. Choi, H. R. B. Raghavendran, N.-Y. Sung et al., "Effect of fucoidan on aspirin-induced stomach ulceration in rats," Chemico-Biological Interactions, vol. 183, no. 1, pp. 249–254, 2010.